{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T10:00:45Z","timestamp":1792404045643,"version":"4.4.0"},"reference-count":35,"publisher":"Elsevier BV","issue":"18","license":[{"start":{"date-parts":[[2017,12,1]],"date-time":"2017-12-01T00:00:00Z","timestamp":1512086400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,12,1]],"date-time":"2017-12-01T00:00:00Z","timestamp":1512086400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Biochemistry"],"published-print":{"date-parts":[[2017,12]]},"DOI":"10.1016\/j.clinbiochem.2017.09.011","type":"journal-article","created":{"date-parts":[[2017,9,19]],"date-time":"2017-09-19T01:00:20Z","timestamp":1505782820000},"page":"1228-1236","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":18,"title":["Sensitive and selective quantification of total and free itraconazole and hydroxyitraconazole in human plasma using ultra-performance liquid chromatography coupled to tandem mass spectrometry"],"prefix":"10.1016","volume":"50","author":[{"given":"Yosuke","family":"Suzuki","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryota","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nobuhiro","family":"Oyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ko","family":"Nonoshita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuhiko","family":"Hashinaga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenji","family":"Umeki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuhki","family":"Sato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9846-7116","authenticated-orcid":false,"given":"Kazufumi","family":"Hiramatsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun-ichi","family":"Kadota","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroki","family":"Itoh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clinbiochem.2017.09.011_bb0005","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1086\/525258","article-title":"Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America","volume":"46","author":"Walsh","year":"2008","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.clinbiochem.2017.09.011_bb0010","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1128\/AAC.01985-15","article-title":"Network meta-analysis and pharmacoeconomic evaluation of fluconazole, itraconazole, posaconazole, and voriconazole in invasive fungal infection prophylaxis","volume":"60","author":"Zhao","year":"2015","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.clinbiochem.2017.09.011_bb0015","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1111\/j.1439-0507.1994.tb00281.x","article-title":"Comparison of in vitro antifungal activity of itraconazole and hydroxy-itraconazole by colorimetric MTT assay","volume":"37","author":"Mikami","year":"1994","journal-title":"Mycoses"},{"key":"10.1016\/j.clinbiochem.2017.09.011_bb0020","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1093\/jac\/45.3.371","article-title":"Antifungal activity of itraconazole compared with hydroxy-itraconazole in vitro","volume":"45","author":"Odds","year":"2000","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.clinbiochem.2017.09.011_bb0025","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1124\/dmd.104.000315","article-title":"Role of itraconazole metabolites in CYP3A4 inhibition","volume":"32","author":"Isoherranen","year":"2004","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.clinbiochem.2017.09.011_bb0030","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1124\/dmd.108.020644","article-title":"Hydroxyitraconazole, formed during intestinal first-pass metabolism of itraconazole, controls the time course of hepatic CYP3A inhibition and the bioavailability of itraconazole in rats","volume":"36","author":"Quinney","year":"2008","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.clinbiochem.2017.09.011_bb0035","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1136\/jcp.50.6.477","article-title":"Itraconazole solution: higher serum drug concentrations and better clinical response rates than the capsule formulation in acquired immunodeficiency syndrome patients with candidosis","volume":"50","author":"Cartledge","year":"1997","journal-title":"J. Clin. Pathol."},{"key":"10.1016\/j.clinbiochem.2017.09.011_bb0040","doi-asserted-by":"crossref","first-page":"4615","DOI":"10.1200\/JCO.2003.04.052","article-title":"Itraconazole prevents invasive fungal infections in neutropenic patients treated for hematologic malignancies: evidence from a meta-analysis of 3,597 patients","volume":"21","author":"Glasmacher","year":"2003","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.clinbiochem.2017.09.011_bb0045","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.2165\/00003088-200645110-00004","article-title":"Population pharmacokinetics of itraconazole and its active metabolite hydroxy-itraconazole in paediatric cystic fibrosis and bone marrow transplant patients","volume":"45","author":"Hennig","year":"2006","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.clinbiochem.2017.09.011_bb0050","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1111\/j.1365-2125.2006.02778.x","article-title":"A D-optimal designed population pharmacokinetic study of oral itraconazole in adult cystic fibrosis patients","volume":"63","author":"Hennig","year":"2007","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.clinbiochem.2017.09.011_bb0055","doi-asserted-by":"crossref","first-page":"461","DOI":"10.2165\/00003088-199835060-00004","article-title":"Optimisation of itraconazole therapy using target drug concentrations","volume":"35","author":"Poirier","year":"1998","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.clinbiochem.2017.09.011_bb0060","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1086\/605499","article-title":"Toxicodynamics of itraconazole: implications for therapeutic drug monitoring","volume":"49","author":"Lestner","year":"2009","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.clinbiochem.2017.09.011_bb0065","doi-asserted-by":"crossref","first-page":"2714","DOI":"10.1128\/AAC.41.12.2714","article-title":"Concentrations in plasma and safety of 7 days of intravenous itraconazole followed by 2 weeks of oral itraconazole solution in patients in intensive care units","volume":"41","author":"Vandewoude","year":"1997","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.clinbiochem.2017.09.011_bb0070","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1093\/jac\/dkm389","article-title":"Antifungal serum concentration monitoring: an update","volume":"61","author":"Goodwin","year":"2008","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.clinbiochem.2017.09.011_bb0075","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1128\/AAC.00705-08","article-title":"Antifungal therapeutic drug monitoring: established and emerging indications","volume":"53","author":"Andes","year":"2009","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.clinbiochem.2017.09.011_bb0080","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1007\/s00277-013-1826-x","volume":"93","author":"Kim","year":"2014","journal-title":"Ann. Hematol."},{"key":"10.1016\/j.clinbiochem.2017.09.011_bb0085","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1248\/bpb.35.971","article-title":"Correlation between plasma ammonia level and serum trough concentration of free valproic acid in patients with epilepsy","volume":"35","author":"Itoh","year":"2012","journal-title":"Biol. Pharm. Bull."},{"key":"10.1016\/j.clinbiochem.2017.09.011_bb0090","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1007\/s40261-015-0334-2","article-title":"Exploratory study of total and free prednisolone plasma exposure and cushingoid appearance, quality of life and biochemical toxicity in adult male kidney transplant recipients","volume":"35","author":"Bergmann","year":"2015","journal-title":"Clin. Drug Investig."},{"key":"10.1016\/j.clinbiochem.2017.09.011_bb0095","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1016\/j.dmpk.2015.10.004","article-title":"Pharmacokinetics and pharmacodynamics of mycophenolic acid in Nagase analbuminemic rats: evaluation of protein binding effects using the modeling and simulation approach","volume":"30","author":"Yoshimura","year":"2015","journal-title":"Drug Metab. Pharmacokinet."},{"key":"10.1016\/j.clinbiochem.2017.09.011_bb0100","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1093\/jac\/11.3.233","article-title":"Effect of protein binding on antibiotic activity in vivo","volume":"11","author":"Merrikin","year":"1983","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.clinbiochem.2017.09.011_bb0105","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1016\/S0891-5520(03)00060-6","article-title":"Antimicrobial tissue concentrations","volume":"17","author":"Liu","year":"2003","journal-title":"Infect. Dis. Clin. N. Am."},{"issue":"Pt. 2","key":"10.1016\/j.clinbiochem.2017.09.011_bb0110","first-page":"102","article-title":"The interactions of drugs and plasma protein","volume":"95","author":"Goldstein","year":"1949","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.clinbiochem.2017.09.011_bb0115","doi-asserted-by":"crossref","first-page":"2953","DOI":"10.1002\/jps.23614","article-title":"Plasma protein binding: from discovery to development","volume":"102","author":"Bohnert","year":"2013","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.clinbiochem.2017.09.011_bb0120","first-page":"361","article-title":"Protein binding of itraconazole and fluconazole in patients with chronic renal failure","volume":"32","author":"Arredondo","year":"1994","journal-title":"Int. J. Clin. Pharmacol. Ther."},{"key":"10.1016\/j.clinbiochem.2017.09.011_bb0125","first-page":"449","article-title":"Protein binding of itraconazole and fluconazole in patients with cancer","volume":"33","author":"Arredondo","year":"1995","journal-title":"Int. J. Clin. Pharmacol. Ther."},{"key":"10.1016\/j.clinbiochem.2017.09.011_bb0130","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1093\/jac\/43.2.305","article-title":"Serum protein binding of itraconazole and fluconazole in patients with diabetes mellitus","volume":"43","author":"Arredondo","year":"1999","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.clinbiochem.2017.09.011_bb0135","author":"US Department of Health and Human Services, Food and Drug Administration"},{"key":"10.1016\/j.clinbiochem.2017.09.011_bb0140","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1007\/s00216-005-0159-6","article-title":"Development of a high-throughput method for the determination of itraconazole and its hydroxy metabolite in human plasma, employing automated liquid-liquid extraction based on 96-well format plates and LC\/MS\/MS","volume":"384","author":"Kousoulos","year":"2006","journal-title":"Anal. Bioanal. Chem."},{"key":"10.1016\/j.clinbiochem.2017.09.011_bb0145","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1515\/cclm-2012-0364","volume":"51","author":"Xiong","year":"2013","journal-title":"Clin. Chem. Lab. Med."},{"key":"10.1016\/j.clinbiochem.2017.09.011_bb0150","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.jchromb.2016.03.039","article-title":"Simultaneous determination of itraconazole, hydroxy itraconazole, keto itraconazole and N-desalkyl itraconazole concentration in human plasma using liquid chromatography with tandem mass spectrometry","volume":"1020","author":"Liang","year":"2016","journal-title":"J. Chromatogr. B Anal. Technol. Biomed. Life Sci."},{"key":"10.1016\/j.clinbiochem.2017.09.011_bb0155","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1177\/00912700122012904","article-title":"Pharmacokinetics of intravenous itraconazole followed by itraconazole oral solution in patients with human immunodeficiency virus infection","volume":"41","author":"Zhao","year":"2001","journal-title":"J. Clin. Pharmacol."},{"key":"10.1016\/j.clinbiochem.2017.09.011_bb0160","author":"US Department of Health and Human Services, Food and Drug Administration"},{"key":"10.1016\/j.clinbiochem.2017.09.011_bb0165","author":"European Medicines Agency"},{"key":"10.1016\/j.clinbiochem.2017.09.011_bb0170","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.jchromb.2012.01.015","article-title":"Simultaneous determination of the azoles voriconazole, posaconazole, isavuconazole, itraconazole and its metabolite hydroxy-itraconazole in human plasma by reversed phase ultra-performance liquid chromatography with ultraviolet detection","volume":"887-888","author":"Wissen","year":"2012","journal-title":"J. Chromatogr. B Anal. Technol. Biomed. Life Sci."},{"key":"10.1016\/j.clinbiochem.2017.09.011_bb0175","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/j.diagmicrobio.2013.03.012","article-title":"A simple, sensitive HPLC-PDA method for the quantification of itraconazole and hydroxy itraconazole in human serum: a reference laboratory experience","volume":"76","author":"Cendejas-Bueno","year":"2013","journal-title":"Diagn. Microbiol. Infect. Dis."}],"container-title":["Clinical Biochemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0009912017305477?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0009912017305477?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,14]],"date-time":"2025-09-14T15:52:05Z","timestamp":1757865125000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0009912017305477"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,12]]},"references-count":35,"journal-issue":{"issue":"18","published-print":{"date-parts":[[2017,12]]}},"alternative-id":["S0009912017305477"],"URL":"https:\/\/doi.org\/10.1016\/j.clinbiochem.2017.09.011","relation":{},"ISSN":["0009-9120"],"issn-type":[{"value":"0009-9120","type":"print"}],"subject":[],"published":{"date-parts":[[2017,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Sensitive and selective quantification of total and free itraconazole and hydroxyitraconazole in human plasma using ultra-performance liquid chromatography coupled to tandem mass spectrometry","name":"articletitle","label":"Article Title"},{"value":"Clinical Biochemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clinbiochem.2017.09.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 The Canadian Society of Clinical Chemists. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}